RUNX1 and acute lymphoblastic leukemia: No Significant Differences in Outcomes Were Observed for the Final Low-Risk Patients With ETV6-RUNX1-Positive ALL or Hyperdiploidy ALL Who Received Two Doses of Daunorubicin Compared With Those Receiving One Dose